Extremely Small Sample Size for Electrophysiology (n=14)
While 106 patients completed initial questionnaires, only 14 underwent the detailed electrophysiological analysis. This tiny sample is insufficient to draw generalizable conclusions about the broader long-COVID population, severely limiting the statistical power and external validity of the 'objectified' findings.
Patients selected for the detailed electrophysiological analysis had 'high scores' on screening tests (COMPASS-31 and mTORONTO), meaning they were pre-selected for having significant symptoms. This makes it difficult to generalize the electrophysiological findings to all long-COVID patients, as it represents a more symptomatic subset.
The authors acknowledge that a skin biopsy, which is a definitive method to confirm small-fiber neuropathy, was not performed. This limits the ability to conclusively determine the nature of the observed neuropathic complaints.
Inability to Evaluate Asymptomatic/Less Symptomatic Patients
The study could not assess patients without autonomic or neuropathic complaints due to 'rejection of hospital admissions due to the pandemic conditions.' This prevents a comprehensive comparison and understanding of the electrophysiological profile across the full spectrum of long-COVID patients.
The study is observational and descriptive. While it identifies associations between long-COVID and certain electrophysiological abnormalities, it cannot establish a causal link or determine if COVID-19 directly causes these specific nerve dysfunctions.